Document:

EXHIBIT 4.2

 

Upon recording, return to:

Ms. Shawne M. Keenan

Sutherland Asbill & Brennan LLP

999 Peachtree Street, N.E.

Atlanta, Georgia 30309-3996

 

PURSUANT TO §44-14-35.1 OF OFFICIAL CODE OF GEORGIA ANNOTATED, THIS INSTRUMENT EMBRACES,

COVERS AND CONVEYS SECURITY TITLE TO AFTER-ACQUIRED PROPERTY OF THE GRANTOR

	
 
    	
 
    
	
 
    	
 
    

 

OGLETHORPE POWER CORPORATION

(AN ELECTRIC MEMBERSHIP CORPORATION),

GRANTOR,

to

U.S. BANK NATIONAL ASSOCIATION,

TRUSTEE

 

SIXTY-NINTH SUPPLEMENTAL

INDENTURE

 

Relating to the

Series 2014 (FFB AB-8) Note and Series 2014 (RUS AB-8) Reimbursement Note

 

Dated as of September 2, 2014

 

FIRST MORTGAGE OBLIGATIONS

	
 
    	
 
    
	
 
    	
 
    

NOTE TO CLERK OF THE GEORGIA SUPERIOR COURT AND GEORGIA TAX COMMISSIONER: THIS INSTRUMENT IS EXEMPT FROM THE INTANGIBLES RECORDING TAX PURSUANT TO THE RULES AND REGULATIONS OF THE STATE OF GEORGIA §§ 560-11-8-.02 AND 560-11-8-.14(A) BECAUSE (A) THIS INSTRUMENT SUPPLEMENTS AND MODIFIES AN EXISTING SECURITY INSTRUMENT AS TO WHICH THE MAXIMUM INTANGIBLES TAX DUE HAS BEEN PREVIOUSLY PAID, AND (B) THIS INSTRUMENT SECURES NOTES, THE HOLDERS OF WHICH ARE THE FEDERAL FINANCING BANK, AN INSTRUMENTALITY OF THE UNITED STATES OF AMERICA, AND THE RURAL UTILITIES SERVICE, AN AGENCY OF THE UNITED STATES OF AMERICA.

 

 

THIS SIXTY-NINTH SUPPLEMENTAL INDENTURE, dated as of September 2, 2014 is between OGLETHORPE POWER CORPORATION (AN ELECTRIC MEMBERSHIP CORPORATION), formerly known as Oglethorpe Power Corporation (An Electric Membership Generation & Transmission Corporation), an electric membership corporation organized and existing under the laws of the State of Georgia, as Grantor (the “Company”), and U.S. BANK NATIONAL ASSOCIATION, a national banking association, as successor to SunTrust Bank, formerly SunTrust Bank, Atlanta, as Trustee (in such capacity, the “Trustee”).

 

WHEREAS, the Company has heretofore executed and delivered to the Trustee an Indenture, dated as of March 1, 1997 (the “Original Indenture”), for the purpose of securing its Existing Obligations and providing for the authentication and delivery of Additional Obligations by the Trustee from time to time under the Original Indenture (capitalized terms used herein and not otherwise defined shall have the meanings assigned to them in the Original Indenture as provided in Section 2.1 hereof);

 

WHEREAS, the Original Indenture has heretofore been amended and supplemented by sixty-eight Supplemental Indentures (the Original Indenture, as heretofore, hereby and hereafter supplemented and modified, hereinafter sometimes called the “Indenture”), and the Original Indenture and the sixty-eight Supplemental Indentures have been recorded as set forth on Schedule 1 attached hereto;

 

WHEREAS, the Company is entering into a Ninth Amended and Restated Loan Contract, dated as of September 2, 2014 (the “Ninth Amended and Restated Loan Contract”) with the United States of America, acting by and through the Administrator of the Rural Utilities Service (“RUS”) which, among other things, provides the terms and conditions of a loan from the FFB in a principal amount of $230,050,000 (the “FFB AB-8 Loan”);

 

WHEREAS, the Company’s obligation to repay the FFB AB-8 Loan will be evidenced by that certain Series 2014 (FFB AB-8) Note, dated the date of its authentication (the “Series 2014 (FFB AB-8) Note”), from the Company to FFB;

 

WHEREAS, RUS will guarantee the Company’s obligation to repay the FFB AB-8 Loan;

 

WHEREAS, the Company will be obligated to reimburse RUS for any payments made to FFB on behalf of the Company in connection with the FFB AB-8 Loan, and such reimbursement obligation by the Company will be evidenced by that certain Series 2014 (RUS AB-8) Reimbursement Note, dated the date of its authentication (the “Series 2014 (RUS AB-8) Reimbursement Note,” and together with the Series 2014 (FFB AB-8) Note, collectively, the “AB-8 Notes”), from the Company to RUS;

 

WHEREAS, the Company desires to execute and deliver this Sixty-Ninth Supplemental Indenture, in accordance with the provisions of the Original Indenture, for the purpose of providing for the creation and designation of the AB-8 Notes as Additional Obligations and specifying the forms and provisions thereof;

 

1

 

WHEREAS, Section 12.1 of the Original Indenture provides that, without the consent of the Holders of any of the Obligations at the time Outstanding, the Company, when authorized by a Board Resolution, and the Trustee, may enter into Supplemental Indentures for the purposes and subject to the conditions set forth in said Section 12.1, including to create additional series of Obligations under the Indenture and to make provisions for such additional series of Obligations; and

 

WHEREAS, all acts and proceedings required by law and by the Articles of Incorporation and Bylaws of the Company necessary to secure under the Indenture the payment of the principal of (and premium, if any) and interest on the AB-8 Notes, to make the AB-8 Notes to be issued hereunder, when executed by the Company, authenticated and delivered by the Trustee and duly issued, the valid, binding and legal obligations of the Company, and to constitute the Indenture a valid and binding lien for the security of the AB-8 Notes, in accordance with its terms, have been done and taken; and the execution and delivery of this Sixty-Ninth Supplemental Indenture have been in all respects duly authorized by the Company;

 

NOW, THEREFORE, THIS SIXTY-NINTH SUPPLEMENTAL INDENTURE WITNESSETH, that, to secure the payment of the principal of (and premium, if any) and interest on the Outstanding Secured Obligations, including, when authenticated and delivered, the AB-8 Notes, to confirm the lien of the Indenture upon the Trust Estate, including property purchased, constructed or otherwise acquired by the Company since the date of execution of the Original Indenture, to secure performance of the covenants therein and herein contained, to declare the terms and conditions on which the AB-8 Notes are secured, and in consideration of the premises thereof and hereof, the Company by these presents does grant, bargain, sell, alienate, remise, release, convey, assign, transfer, mortgage, hypothecate, pledge, set over and confirm to the Trustee, and its successors and assigns in the trust created thereby and hereby, in trust, all property, rights, privileges and franchises (other than Excepted Property or Excludable Property) of the Company, whether now owned or hereafter acquired, of the character described in the Granting Clauses of the Original Indenture, wherever located, including all such property, rights, privileges and franchises acquired since the date of execution of the Original Indenture, including, without limitation, all property described in Exhibit A attached hereto; subject to all exceptions, reservations and matters of the character referred to in the Indenture, and does grant a security interest therein for the purposes expressed herein and in the Indenture subject in all cases to Sections 5.2 and 11.2B of the Original Indenture, and to the rights of the Company under the Indenture including the rights set forth in Article V thereof; but expressly excepting and excluding from the lien and operation of the Indenture all properties of the character specifically excepted as “Excepted Property” or “Excludable Property” in the Indenture to the extent contemplated thereby.

 

PROVIDED, HOWEVER, that if, upon the occurrence of an Event of Default, the Trustee, or any separate trustee or co-trustee appointed under Section 9.14 of the Original Indenture or any receiver appointed pursuant to statutory provision or order of court, shall have entered into possession of all or substantially all of the Trust Estate, all the Excepted Property described or referred to in Paragraphs A through H, inclusive, of “Excepted Property” in the Original Indenture then owned or thereafter acquired by the Company, shall immediately, and, in the case of any Excepted Property described or referred to in Paragraphs I, J, L, N and P of “Excepted Property” in the Original Indenture (excluding the property described in Section 2 of

 

2

 

Exhibit B in the Original Indenture) upon demand of the Trustee or such other trustee or receiver, become subject to the lien of the Indenture to the extent permitted by law, and the Trustee or such other trustee or receiver may, to the extent permitted by law, at the same time likewise take possession thereof, and whenever all Events of Default shall have been cured and the possession of all or substantially all of the Trust Estate shall have been restored to the Company, such Excepted Property shall again be excepted and excluded from the lien of the Indenture to the extent and otherwise as hereinabove set forth and as set forth in the Indenture.

 

The Company may, however, pursuant to the Granting Clause Third of the Original Indenture subject to the lien of the Indenture any Excepted Property or Excludable Property, whereupon the same shall cease to be Excepted Property or Excludable Property.

 

TO HAVE AND TO HOLD all such property, rights, privileges and franchises hereby and hereafter (by a Supplemental Indenture or otherwise) granted, bargained, sold, alienated, remised, released, conveyed, assigned, transferred, mortgaged, hypothecated, pledged, set over or confirmed as aforesaid, or intended, agreed or covenanted so to be, together with all the tenements, hereditaments and appurtenances thereto appertaining (said properties, rights, privileges and franchises, including any cash and securities hereafter deposited or required to be deposited with the Trustee (other than any such cash which is specifically stated in the Original Indenture not to be deemed part of the Trust Estate) being part of the Trust Estate), unto the Trustee, and its successors and assigns in the trust created by the Indenture, forever.

 

SUBJECT, HOWEVER, to (i) Permitted Exceptions and (ii) to the extent permitted by Section 13.6 of the Original Indenture as to property hereafter acquired (a) any duly recorded or perfected prior mortgage or other lien that may exist thereon at the date of the acquisition thereof by the Company and (b) purchase money mortgages, other purchase money liens, chattel mortgages, conditional sales agreements or other title retention agreements created by the Company at the time of acquisition thereof.

 

BUT IN TRUST, NEVERTHELESS, with power of sale, for the equal and proportionate benefit and security of the Holders from time to time of all the Outstanding Secured Obligations without any priority of any such Obligation over any other such Obligation and for the enforcement of the payment of such Obligations in accordance with their terms.

 

UPON CONDITION that, until the happening of an Event of  Default and subject to the provisions of Article V of the Original Indenture, and not in limitation of the rights elsewhere provided in the Indenture, including the rights set forth in Article V of the Original Indenture, the Company shall be permitted to (i) possess and use the Trust Estate, except cash, securities, Designated Qualifying Securities and other personal property deposited, or required to be deposited, with the Trustee, (ii) explore for, mine, extract, separate and dispose of coal, ore, gas, oil and other minerals, and harvest standing timber, and (iii) receive and use the rents, issues, profits, revenues and other income, products and proceeds of the Trust Estate.

 

3

 

THE INDENTURE, INCLUDING THIS SIXTY-NINTH SUPPLEMENTAL INDENTURE, is given to secure the Outstanding Secured Obligations, and is intended to operate and is to be construed as a deed passing title to the Trust Estate and is made under the provisions of the laws of the State of Georgia relating to deeds to secure debt, and not as a mortgage or deed of trust, and is given to secure the Outstanding Secured Obligations.  Should the indebtedness secured by the Indenture be paid according to the tenor and effect thereof when the same shall become due and payable and should the Company perform all covenants contained in the Indenture in a timely manner, then the Indenture shall be canceled and surrendered.

 

AND IT IS HEREBY COVENANTED AND DECLARED that the AB-8 Notes are to be authenticated and delivered and the Trust Estate is to be held and applied by the Trustee, subject to the covenants, conditions and trusts set forth herein and in the Original Indenture, and the Company does hereby covenant and agree to and with the Trustee, for the equal and proportionate benefit of all Holders of the Outstanding Secured Obligations, as follows:

 

ARTICLE I

THE AB-8 NOTES AND
 CERTAIN PROVISIONS RELATING THERETO

 

Section 1.1     Authorization and Terms of the Series 2014 (FFB AB-8) Note.

 

There shall be created and established an Additional Obligation in the form of a future advance promissory note known as and entitled the “Series 2014 (FFB AB-8) Note,” the form, terms and conditions of which shall be substantially as set forth in or determined by the method prescribed pursuant to this Section and Section 1.2 hereof.  The face principal amount of the Series 2014 (FFB AB-8) Note is limited to $230,050,000.

 

The Series 2014 (FFB AB-8) Note, when duly executed and issued by the Company, and authenticated and delivered by the Trustee and received and held by FFB, will be equally and proportionately secured under the Indenture with all other Outstanding Secured Obligations.

 

The Series 2014 (FFB AB-8) Note shall be dated the date of its authentication.  The Series 2014 (FFB AB-8) Note shall have a final maturity date of December 31, 2040, and each advance under the Series 2014 (FFB AB-8) Note shall bear interest from the date of advance until the maturity date for such advance at rates calculated as provided for in the form of note prescribed pursuant to Section 1.2 hereof.  The Series 2014 (FFB AB-8) Note shall be authenticated and delivered to, and made payable to, FFB.

 

All payments, including prepayments, made on the Series 2014 (FFB AB-8) Note shall be made as provided in the Series 2014 (FFB AB-8) Note and the Ninth Amended and Restated Loan Contract (and shall not be governed by the provisions of Section 1.14 or Article XIV of the Original Indenture), and shall be made in lawful money of the United States of America which will be immediately available on the date payment is due.

 

4

 

Section 1.2     Form of the Series 2014 (FFB AB-8) Note.

 

The Series 2014 (FFB AB-8) Note and the Trustee’s certificate of authentication for the Series 2014 (FFB AB-8) Note shall be substantially in the form set forth in an Officers’ Certificate to be delivered to the Trustee by the Company, which shall establish the terms and conditions of the Series 2014 (FFB AB-8) Note pursuant to Section 2.1 of the Original Indenture, with such appropriate insertions, omissions, substitutions and other variations as are required or permitted in the Original Indenture.

 

Pursuant to Section 1.20 of the Original Indenture, the United States of America, acting by and through the Administrator of RUS, shall be, and shall have the rights of, the Holder of the Series 2014 (FFB AB-8) Note for all purposes under the Indenture at all times during which the Series 2014 (FFB AB-8) Note continues to be guaranteed by the United States of America, acting by and through the Administrator of RUS.

 

Section 1.3     Authorization and Terms of the Series 2014 (RUS AB-8) Reimbursement Note.

 

There shall be created and established an Additional Obligation in the form of a reimbursement note known as and entitled the “Series 2014 (RUS AB-8) Reimbursement Note,” the form, terms and conditions of which shall be substantially as set forth in or determined by the method prescribed pursuant to this Section and Section 1.4 hereof.

 

The Series 2014 (RUS AB-8) Reimbursement Note, when duly executed and issued by the Company, and authenticated and delivered by the Trustee and received and held by the Holder thereof, will be equally and proportionately secured under the Indenture with all other Outstanding Secured Obligations.

 

The Series 2014 (RUS AB-8) Reimbursement Note shall be dated the date of its authentication.  The Series 2014 (RUS AB-8) Reimbursement Note shall mature and shall bear interest for the periods and at the rates calculated as provided for in the form of note prescribed pursuant to Section 1.4 hereof.  The Series 2014 (RUS AB-8) Reimbursement Note shall be authenticated and delivered to, and made payable to, the United States of America, acting by and through the Administrator of RUS.

 

All payments, including prepayments, made on the Series 2014 (RUS AB-8) Reimbursement Note shall be made as provided in the Series 2014 (RUS AB-8) Reimbursement Note and the Ninth Amended and Restated Loan Contract (and shall not be governed by the provisions of Section 1.14 or Article XIV of the Original Indenture) to the United States of America, acting by and through the Administrator of RUS, at the United States Treasury, Washington, D.C., and shall be made in lawful money of the United States of America which will be immediately available on the date payment is due.

 

The Series 2014 (RUS AB-8) Reimbursement Note is an Additional Obligation issued by the Company for the purpose of evidencing the Company’s obligation to reimburse the United States of America, acting by and through the Administrator of RUS, for all amounts paid, or for any advances or loans made to or on behalf of the Company, on account of the guarantee by the

 

5

 

United States of America, pursuant to the Rural Electrification Act of 1936, as amended, of the Series 2014 (FFB AB-8) Note, and related interest, fees, costs, penalties, charges and other amounts, and constitutes an “RUS Reimbursement Obligation” as described in Section 4.9 of the Original Indenture.

 

Section 1.4     Form of the Series 2014 (RUS AB-8) Reimbursement Note.

 

The Series 2014 (RUS AB-8) Reimbursement Note and the Trustee’s certificate of authentication for such Series 2014 (RUS AB-8) Reimbursement Note shall be substantially in the form set forth in an Officers’ Certificate to be delivered to the Trustee by the Company, which shall establish the terms and conditions of the Series 2014 (RUS AB-8) Reimbursement Note pursuant to Section 2.1 of the Original Indenture, with such appropriate insertions, omissions, substitutions and other variations as are required or permitted in the Indenture.

 

ARTICLE II

 

MISCELLANEOUS

 

Section 2.1     Supplemental Indenture.  This Sixty-Ninth Supplemental Indenture is executed and shall be construed as an indenture supplemental to the Original Indenture, and shall form a part thereof, and the Original Indenture, as heretofore supplemented and as hereby supplemented and amended, is hereby confirmed.  Except to the extent inconsistent with the express terms of this Sixty-Ninth Supplemental Indenture, the Ninth Amended and Restated Loan Contract and the AB-8 Notes, all of the provisions, terms, covenants and conditions of the Indenture generally applicable to the payment or redemption of all Obligations shall be applicable to the AB-8 Notes to the same extent as if specifically set forth herein.  All capitalized terms used in this Sixty-Ninth Supplemental Indenture but not defined herein shall have the same meanings ascribed to them in the Original Indenture, as such terms may have been or may be amended or modified from time to time pursuant to the Indenture, except in cases where the context clearly indicates otherwise.  All references herein to Sections, Articles, definitions or other provisions of the Original Indenture shall be to such Sections, Articles, definitions or other provisions as they may be amended or modified from time to time pursuant to the Indenture.

 

Section 2.2     Recitals.  All recitals in this Sixty-Ninth Supplemental Indenture are made by the Company only and not by the Trustee; and all of the provisions contained in the Original Indenture, in respect of the rights, privileges, immunities, powers and duties of the Trustee shall be applicable in respect hereof as fully and with like effect as if set forth herein in full.

 

Section 2.3     Successors and Assigns.  Whenever in this Sixty-Ninth Supplemental Indenture any of the parties hereto is named or referred to, this shall, subject to the provisions of Articles IX and XI of the Original Indenture, be deemed to include the successors and assigns of such party, and all the covenants and agreements in this Sixty-Ninth Supplemental Indenture contained by or on behalf of the Company, or by or on behalf of the Trustee shall, subject as aforesaid, bind and inure to the respective benefits of the respective successors and assigns of such parties, whether so expressed or not.

 

6

 

Section 2.4        No Rights, Remedies, Etc.  Nothing in this Sixty-Ninth Supplemental Indenture, expressed or implied, is intended, or shall be construed, to confer upon, or to give to, any person, firm or corporation, other than the parties hereto and the Holders of the Outstanding Secured Obligations, any right, remedy or claim under or by reason of this Sixty-Ninth Supplemental Indenture or any covenant, condition, stipulation, promise or agreement hereof, and all the covenants, conditions, stipulations, promises and agreements in this Sixty-Ninth Supplemental Indenture contained by or on behalf of the Company shall be for the sole and exclusive benefit of the parties hereto, and of the Holders of Outstanding Secured Obligations.

 

Section 2.5     Counterparts.  This Sixty-Ninth Supplemental Indenture may be executed in several counterparts, each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts, or as many of them as the Company and the Trustee shall preserve undestroyed, shall together constitute but one and the same instrument.

 

Section 2.6     Security Agreement and Financing Statement.  To the extent permitted by applicable law, this Sixty-Ninth Supplemental Indenture shall be deemed to be a Security Agreement and Financing Statement whereby the Company grants to the Trustee a security interest in all of the Trust Estate that is personal property or fixtures under the Uniform Commercial Code, as adopted or hereafter adopted in one or more of the states in which any part of the properties of the Company are situated.  The mailing address of the Company, as debtor is:

 

Oglethorpe Power Corporation

(An Electric Membership Corporation)

2100 East Exchange Place

Tucker, Georgia 30084-5336,

 

and the mailing address of the Trustee, as secured party, is:

 

U.S. Bank National Association

Attention: Corporate Trust Services

1349 West Peachtree Street, NW

Suite 1050, Two Midtown Plaza

Atlanta, Georgia 30309

 

 

[Signatures Begin on Next Page.]

 

7

 

IN WITNESS WHEREOF, the parties hereto have caused this Sixty-Ninth Supplemental Indenture to be duly executed under seal as of the day and year first written above.

 

 

	
Company:
    	
OGLETHORPE POWER CORPORATION (AN ELECTRIC MEMBERSHIP   CORPORATION), an electric membership corporation organized   under the laws of the State of Georgia
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Elizabeth B. Higgins
    
	
 
    	
 
    	
Elizabeth   B. Higgins
    
	
 
    	
 
    	
Executive   Vice President and
    
	
 
    	
 
    	
Chief   Financial Officer
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Signed,   sealed and delivered
    	
Attest:
    	
/s/   Patricia N. Nash
    
	
by   the Company in the presence of:
    	
 
    	
Patricia   N. Nash
    
	
 
    	
 
    	
Secretary
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/ Paulette J. Hurteau
    	
 
    	
[CORPORATE SEAL]
    
	
Witness
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/ Sharon H. Wright
    	
 
    	
 
    	
 
    
	
Notary   Public
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
(Notarial   Seal)
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
My   commission expires:
    	
October 14,   2015
    	
 
    	
 
    	
 
    
					

 

 

[Signatures Continued on Next Page.]

 

 

[Signatures Continued from Previous Page]

 

 

	
Trustee:
    	
U.S. BANK NATIONAL ASSOCIATION,
    
	
 
    	
a   national banking association
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/  Jack Ellerin
    
	
 
    	
 
    	
Authorized   Agent
    
	
 
    	
 
    	
 
    
	
Signed   and delivered
    	
 
    	
 
    
	
by   the Trustee in the
    	
 
    	
 
    
	
presence   of:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/ David M. Johnson
    	
 
    	
 
    
	
Witness
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/ Felicia H. Powell
    	
 
    	
 
    
	
Notary   Public
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
(Notarial   Seal)
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
My   commission expires:
    	
July 2,   2018
    	
 
    	
 
    
					

 

 

Exhibit A

 

All property (other than Excepted Property and Excludable property) of the Company in the Counties of Appling, Burke, Carroll, Coweta, DeKalb, Floyd, Hart, Heard, Monroe, Murray, Talbot, Toombs, Warren, Washington and Whitfield, State of Georgia, whether now owned or hereafter acquired, including the following property to wit:

 

All that certain tract or parcel of land situate, lying and being in Land Lot 205, Third Land District, Coweta County, Georgia, containing 2.98 acres, and being the same property as that shown on a survey for Otis Ford, dated September 14,1990, made by Robert P. Driggs, Registered Land Surveyor, and being of record in Plat Book 49, page 176, Coweta County, Georgia records. Said property is more particularly described according to said plat as follows:

 

To arrive at the True Point of Beginning, begin at the intersection of the Northerly side of the right of way of Midway Road (80’ Right of Way) with the East Line of Land Lot 205, and run thence South 73 degrees 53 Minutes 30 Seconds West 18.54 feet along said Right of Way to an iron pin set; said iron pin being located at the True Point of Beginning for the property hereinafter described,

 

From said iron pin set and True Point of Beginning, run thence South 73 degrees 53 minutes 30 seconds West 266.80 feet along the Northerly side of the Right of Way of said Midway Road to a point; thence continuing along the Northerly side of said Right of Way South 80 degrees 07 minutes 30 seconds West 67.49 feet to a point; thence continuing along the Northerly side of said Right of Way South 87 degrees 05 minutes 45 seconds West 37.79 feet to a point; thence continuing along the Northerly side of said Right of Way North 87 degrees 00 minutes 00 seconds west 47.08 feet to an iron pin set; thence North 01 degrees 58 minutes 15 seconds West 150.00 feet to an iron pin set; thence North 84 degrees 39 minutes 30 seconds west 100.0 feet to an iron pin set; thence North 01 degrees 58 minutes 15 seconds West 199.47 feet to an iron pin set; thence North 85 degrees 38 minutes 00 seconds East 230.19 feet to an iron pin set; thence South 44 degrees 21 minutes 15 seconds East 55.78 feet to a point, thence South 53 degrees 31 minutes 30 seconds East 37.96 feet to a point; thence South 59 degrees 51 minutes 15 seconds East 101.85 feet to a point; thence South 55 degrees 34 minutes 15 seconds East 52.71 feet to a point; thence South 50 degrees 14 minutes 15 seconds East 38.87 feet to a point; thence South 34 degrees 19 minutes 00 seconds East 32.35 feet to a point; thence South 22 degrees 50 minutes 15 seconds East 104.23 feet to the iron pin set at the True Point of Beginning.

 

Subject to restrictive covenants and general utility easements of record.

 

 

Schedule 1

 

RECORDING INFORMATION

FOR

                           COUNTY, GEORGIA

 

	
DOCUMENT
    	
 
    	
RECORDING
   INFORMATION
    	
 
    	
DATE OF
   RECORDING
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Original   Indenture
    	
 
    	
 
    	
 
    	
 
    
	
First   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Second   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Third   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Fourth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Fifth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Sixth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Seventh   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Eighth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Ninth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Tenth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Eleventh   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Twelfth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Thirteenth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Fourteenth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Fifteenth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Sixteenth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Seventeenth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Eighteenth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Nineteenth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Twentieth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Twenty-First   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Twenty-Second   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Twenty-Third   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Twenty-Fourth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Twenty-Fifth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    

 

 

	
DOCUMENT
    	
 
    	
RECORDING
   INFORMATION
    	
 
    	
DATE OF
   RECORDING
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Twenty-Sixth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Twenty-Seventh   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Twenty-Eighth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Twenty-Ninth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Thirtieth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Thirty-First   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Thirty-Second   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Thirty-Third   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Thirty-Fourth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Thirty-Fifth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Thirty-Sixth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Thirty-Seventh   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Thirty-Eighth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Thirty-Ninth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Fortieth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Forty-First   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Forty-Second   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Forty-Third   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Forty-Fourth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Forty-Fifth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Forty-Sixth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Forty-Seventh   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Forty-Eighth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Forty-Ninth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Fiftieth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Fifty-First   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Fifty-Second   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Fifty-Third   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Fifty-Fourth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Fifty-Fifth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    

 

 

	
DOCUMENT
    	
 
    	
RECORDING
   INFORMATION
    	
 
    	
DATE OF
   RECORDING
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Fifty-Sixth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Fifty-Seventh   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Fifty-Eighth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Fifty-Ninth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Sixtieth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Sixty-First   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Sixty-Second   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Sixty-Third   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Sixty-Fourth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Sixty-Fifth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Sixty-Sixth   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Sixty-Seventh   Supplemental Indenture
    	
 
    	
 
    	
 
    	
 
    
	
Sixty-Eighth   Supplemental IndentureEX-10.2

 Exhibit 10.2 

Confidential Materials omitted and filed separately with the 

Securities and Exchange Commission. Double asterisks denote omissions. 

SUPPLY AGREEMENT 
 This
Supply Agreement (“Agreement”), effective as of July 29, 2014 (the “Effective Date”), is made by and between Durata Therapeutics International B.V., a company registered in the Netherlands with offices at
Spaces Zuidas II, Barbara Strozzilaan 101, 1083 HN Amsterdam, the Netherlands (“Durata”) and A.C.R.A.F. S.p.A.—a company with only one shareholder under direction and coordination of Finaf S.p.A., a company duly organized and
validly existing under the laws of Italy, with its principal place of business at Viale Amelia, 70—00181 Rome Italy (“Angelini”). 

WHEREAS, simultaneously with the execution of this Agreement, Durata and Angelini executed the License Agreement pursuant to Section 7.1
of which Angelini undertakes Durata will be the exclusive supplier of the Product to Angelini in accordance with the terms and conditions set forth below. 

NOW THEREFORE, in consideration of the above stated premises and of the mutual covenants and agreements set forth below, and intending to be
legally bound by the provisions of this Agreement, the Parties hereby agree as follows: 
 ARTICLE I 

DEFINITIONS 
 Capitalized
terms not otherwise defined herein shall have the meanings set forth in the License Agreement, unless otherwise specified. When used in this Agreement, the capitalized terms listed in this ARTICLE I shall have the following meanings: 

1.1    “Agreed Tolerance” has the meaning set out in Section 3.1 (c). 

1.2    “Agreement” means this Supply Agreement, including any exhibits or schedules hereto, as such may
be amended from time to time, in writing, by mutual agreement of the Parties. 
 1.3    “Authorized
Manufacturer” means the manufacturer of the Products for each country of the Territory as appointed by Durata and listed and described in Exhibit C authorized by EMA as well as by the local health authorities, which shall include the
Back Up Manufacturers when they are ultimately qualified by EMA and the local health authorities. 

1.4    “Back Up Manufacturers” has the meaning set forth in Section 2.6. 

1.5    “Business Day” means Monday, Tuesday, Wednesday, Thursday or Friday of any week other than such
days which constitute an official Italian or Dutch public or United States federal government holiday. 

1.6    “Catastrophic Supply Failure” has the meaning set forth in Section 3.7 (b). 

 1.7    “Certificate of Analysis” means a certificate
provided by Durata to Angelini for a Product certifying that the Product Lot meets the relevant Specifications. 

1.8    “Commercially Reasonable Efforts” means that degree of skill, effort, expertise, and
resources that a global pharmaceutical company under similar circumstances, in the matters addressed herein would reasonably utilize and otherwise apply with respect to fulfilling a particular obligation. 

1.1    “Compound” shall mean dalbavancin, as described with greater specificity in Exhibit A. 

1.9    “Effective Date” has the meaning set forth in the introductory paragraph hereto. 

1.10    “Facility(ies)” means the manufacturing facility(ies) used by Durata’s contract
manufacturers to practice the Processes as described in the Exhibit B. 
 1.11    “Firm
Forecast” has the meaning set forth in Section 3.1(c). 
 1.12    “Firm Order” has the meaning
set forth in Section 3.1(b). 
 1.13    “INCOTERMS 2010” means the specifications of the obligations
for delivering goods in international contracts, as issued by the International Chamber of Commerce. 

1.14    “License Agreement” means that certain License Agreement by and between Durata and Angelini,
dated as of             , 2014. 

1.15    “Master Batch Record” means the master batch record of Durata, which shall include, without
limitation, instructions for manufacturing, packaging, and in-process testing and release testing for Product, as amended from time to time. 

1.16    “Non-Conforming Product” means Product that fails to conform to the Product Specifications. 

1.17    “Notices” has the meaning set forth in Section 10.9. 

1.18    “Planned Order” has the meaning set forth in Section 3.1(d). 

1.19    “Process” or “Processing” means the act of purification, preparation, filling,
storing, testing, and any other pharmaceutical manufacturing procedures, or any part thereof, involved in manufacturing the Products. 

1.20    “Product” means a pharmaceutical composition to be marketed by Angelini in the Territory
containing the Compound in (i) finished goods form with finished packaging and labelling as approved by the EMA and/or each country in the Territory (“Finished Goods Form”) or (ii) if agreed by the Parties pursuant to
Section 2.1(b), bulk form without packaging or labelling (“Bulk Form”) as described in the Exhibit D. 

 1.21    “Product Forecast” has the meaning set forth in
Section 3.1(a). 
 1.22    “Product Lot” means one production lot of the Product based on
starting inputs, as stated in the Master Batch Record.  
 1.23    “Product Price” has the
meaning set forth in Section 5.1. 
 1.24    “Product Specifications” means the manufacturing
and quality specifications, including, without limitation, unit descriptions, which the Product must meet in order to be released for distribution, as approved by the EMA, as set forth in the Registration Dossier as well as in the Quality Agreement,
as amended from time to time. 
 1.25    “Purchase Order” has the meaning set forth in Section
3.4. 
 1.26    “Quality Agreement” means the agreement described in Section 2.4. 

1.27    “Registration Dossier” shall mean with respect to the Product, the package of technical
and clinical information and data concerning such Product (and relevant manufacturing site) that is prepared by Durata for use in seeking any relevant Regulatory Approval. 

1.28    “Specifications” means, with respect to the Product, the relevant Master Batch Record and
Product Specifications in effect from time to time during the Term as described, as of the Effective Date, in Exhibit E. 

1.29    “Supply Failure” has the meaning set forth in Section 3.7. 

1.30    “Term” has the meaning set forth in Section 6.1 and for the avoidance of any doubt, shall
mean the Initial Termas well as the Extended Term as set forth in Section 6.2. 

1.31    “Territory” shall mean Italy (including San Marino and the Vatican City), Albania,
Andorra, Armenia, Austria, Azerbaijan, Belarus, Bosnia-Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Georgia, Greece, Hungary, Kazakhstan, Kosovo, Kyrgzstan, Lithuania, Latvia, Macedonia, Moldova, Montenegro, Poland, Portugal, Romania,
Russia, Serbia, Slovenia, Slovak Republic, Spain, Tajikistan, Turkey, Turkmenistan, Ukraine, and Uzbekistan. 
 ARTICLE II 

GENERAL SCOPE OF SERVICES 

2.1    Requirements. 

(a)    Except as set forth in Section 3.7(b), during the Term of this Agreement, Angelini shall purchase Product and
Durata shall manufacture and supply all of Angelini’s requirements for Product. 

 (b)    As at the Effective Date, Durata shall manufacture the Product using
the Authorized Manufacturers and supply the Product to Angelini in Finished Goods Form released and ready for sales in the Territory. At any time during the Term of this Agreement, Angelini may notify Durata in writing that it wishes for Durata to
manufacture and supply the Product in Bulk Form. The Parties, shall promptly following the receipt of any notice under this Section 2.1(b), discuss in good faith and agree the terms applicable to the supply by Durata to Angelini of Bulk
Product. 
 2.2    Inspections. 

(a)    Durata agrees to allow, after consultation, Angelini or parties contracted by Angelini and reasonably acceptable by
Durata to conduct inspections reasonably required in connection with the manufacture of the Products. Angelini shall have the right, upon no less than [**] Business Days’ prior written notice to Durata, to conduct, during normal business hours
and on the same dates and at the same times as any audit conducted by Durata, a quality assurance audit and inspection of Durata’s records and the Third Party production facilities used in the manufacture of the Products. Angelini shall comply,
and shall ensure that its auditors comply, with the terms of any confidentiality or non-disclosure agreement requested by any of Durata’s Third Party production facilities and shall treat any Information received during any such audit as
Confidential Information in accordance with the terms of Article VIII of the License Agreement. Except as expressly provided in the remaining provisions of this Section 2.2, Angelini may audit and inspect each facility that is used for any
Processing of the Products by or on behalf of Durata pursuant to this Agreement no more than [**] years. More frequent audits by Angelini will be permitted by Durata in case of critical non conformities of the Products supplied hereunder or, if
based on less than satisfactory results for previous audits of Durata facilities, subject to [**] Business Days’ prior written notice to Durata, and subject to Durata’s agreement, such agreement not to be unreasonably withheld. The
duration of such audits shall not exceed [**] days per facility and such audits shall be performed by no more than [**] per facility. Authorized Manufacturers shall hold all necessary manufacturing authorizations granted by relevant European
Government Authorities for the activities indicated in such manufacturing authorizations. Any Authorized Manufacturers (located inside and outside the EU) shall hold and maintain local authorizations, as required by local Laws. Durata will supply an
EU-cGMP certification for all of the Authorized Manufacturers and for the relevant pharmaceutical finished dosage form released by a European Health Authority. Durata states and warrants that the Product shall be manufactured only by Authorized
Manufacturers described in Exhibit C, as such list may be modified by the mutual agreement of the Parties, not to be unreasonably withheld. 

(b)    Angelini agrees to allow, after consultation, Durata or parties contracted by Durata and reasonably acceptable by
Angelini to conduct inspections reasonably required in connection with Angelini’s storage and distribution of the 

 
Products. Durata shall have the right, upon no less than [**] Business Days’ prior written notice to Angelini, to conduct, during normal business hours and on the same dates and at the same
times as any audit conducted by Angelini, a quality assurance audit and inspection of Angelini’s records and the storage and distribution facilities used in the storage and distribution of the Products (including any Third Party facilities used
by Angelini). Durata shall comply, and shall ensure that its auditors comply, with the terms of any confidentiality or non-disclosure agreement requested by any of Angelini’s Third Party facilities and shall treat any Information received
during any such audit as Confidential Information in accordance with the terms of Article VIII of the License Agreement. Except as expressly provided in the remaining provisions of this Section 2.2, Durata may audit and inspect each facility
that is used for any storage and distribution of the Products by or on behalf of Angelini pursuant to this Agreement no more than [**] years. More frequent audits by Durata will be permitted by Angelini in case of critical non conformities in the
storage and handling of the Products or, if based on less than satisfactory results for previous audits of Angelini facilities, subject to [**] Business Days’ prior written notice to Angelini, and subject to Angelini’s agreement, such
agreement not to be unreasonably withheld. The duration of such audits shall not exceed [**] days per facility and such audits shall be performed by no more than [**] per facility. 

2.3    Specifications. 

(a)    Durata shall, and shall ensure that its Authorized Manufacturers shall, Process the Products in accordance with all
applicable Laws, manufacturing authorizations and the Specifications. Products provided by Durata pursuant to this Agreement shall conform to the Specifications at the time of delivery by Durata. Durata is responsible for an Annual Product Quality
Review, on-going stability and the audit of the active pharmaceutical ingredients manufacturer (for GMP requirement) and to ensure that Authorized Manufacturers comply with all of the EU-GMP/gdp requirements. 

(b)    The residual shelf life of the Product at the delivery date shall not be less than [**]% of the total shelf life of
the Product, based upon the assumption that the shelf life shall be [**] months (similar to the already granted by FDA in the United States of America). 

(c)    Except as otherwise agreed by the Parties pursuant to Section 2.1(b), Durata shall package the Products in
Finished Goods Form released and ready to sale with labels and other packaging in accordance with all applicable Laws and the Specifications. Angelini shall develop and provide to Durata all artwork, labelling (including all special labelling, such
as Bollino), product inserts and other packaging designs for the Product and shall ensure that all such artwork, labelling, product inserts and other packaging is in compliance with all Regulatory Approvals for the Product and all applicable Law in
each respective country in the Territory and is reasonably acceptable to Durata. Additionally, Angelini shall supply to Durata sufficient quantities of any and all special packaging and labeling required for any country in the Territory, including,
but not limited to, required pricing imprinting, Italian Bollini labels, etc. These items must be supplied to Durata with sufficient lead time in order to include on the Product in Finished Goods Form. After receipt of the Product, Angelini may not
re-package or re-label the Product without the prior written approval of Durata, not to be unreasonably withheld. 

 (d)    Durata shall retain samples of each batch of the Products supplied to
Angelini pursuant to this Agreement as described in the Quality Agreement and manage any stability programs required by commercially reasonable regulatory requirements including storage, testing and reporting, as necessary at its cost. 

(e)    Durata may implement Process, Specification and all other changes as approved or required by applicable Law
(including by the EMA and European Union). Angelini must comply with any such changes in the Territory as requested by Durata. Any Process or Specification change requested by Angelini for any country in the Territory which is not subject to the
jurisdiction of the EMA shall be discussed and shall require Durata’s prior written agreement to implement. The costs and expenses for the implementation of any such changes will be borne by the party requesting the change; provided,
notwithstanding Section 5.1, any cost incurred by Durata as a result of changes required by applicable Law, will be appropriately reflected in changes to the Price. 

(f)    Any documentation or materials requested by Angelini for use with the Products for any country in the Territory
which is not subject to the jurisdiction of the EMA shall be supplied by Durata free of any costs if already available. If such documentation or materials are not already available, Angelini will bear any incremental costs of Durata in supplying
such documentation or materials. 
 2.4    Quality Agreement. The Parties shall discuss and agree, where
appropriate, on specific procedures and guidelines for batch release, quality control testing and quality assurance review, acceptance testing, and other roles and responsibilities related to the Compound and the Products, which procedures and
guidelines shall be set forth in the Quality Agreement. Durata guarantees that Authorized Manufacturers: 
 a)    will
comply with EU Directive 2001/83 as amended, EU-GMP (for active pharmaceutical ingredient and finished product) and relevant ICH/EMA guidelines (e.g. risk assessment for excipients, elemental impurities, etc.) and (for all the countries outside the
EU territory) with the local GMP; and 
 b)    will be duly authorized as a batch releaser in accordance with the local
Law of the Territory 
 Further, the Quality Agreement shall reflect the terms detailed in the Exhibit F. 

2.5    Back up Manufacturer. Durata shall use its Commercially Reasonable Efforts to qualify with the EMA as well
as to the other health authorities in the Territory an appropriate back up manufacturer for the Compound and an appropriate back up manufacturer for the Product (collectively referred to as the “Back up Manufacturer”) as soon as
reasonably practicable after the Effective Date. 

 ARTICLE III 

FORECASTS AND PURCHASE ORDERS 

3.1    Monthly Forecast. 

(a)    Product Forecast. Within [**] days from the date that EMA Regulatory Approval is granted and thereafter on
or before the last Business Day of each calendar month, Angelini shall submit to Durata an [**] month rolling forecast that sets forth the total quantity of Products that Angelini either has ordered, desires to order, or expects to order from Durata
within the next [**] month period (“Product Forecast”). For the avoidance of doubt, the Product Forecast shall not include the calendar month during which the Product Forecast is provided. The first Product Forecast shall be
delivered to Durata within [**] months from the date on which the EMA Regulatory Approvals are obtained by Durata as described in Section 4.1 (a) of the License Agreement. 

(b)    Firm Orders. The forecast quantities for the [**] calendar months only in a Product Forecast shall include
the requested delivery dates and shall be binding upon the Parties (“Firm Orders”). 

(c)    Non-Binding Forecasts. The forecast quantities for the [**] up to the [**] month in a Product Forecast are
non-binding orders (“Planned Orders”), but orders which Angelini reasonably believes are likely over time to become Firm Orders. Angelini may revise the quantity and timing of Planned Orders at each scheduled update, provided that
any such revision to a Planned Order for a given Calendar Month (whether increase or reduction) may not in any circumstances exceed a maximum of [**] per cent ([**]%) (“Agreed Tolerance”) from the quantity first specified when such
Calendar Month was the [**] month in the Product Forecast. Durata shall be obliged to satisfy the relevant requirements of such Firm Order. 

3.2    Information for long-term Planning. By [**] in each Calendar Year, Angelini shall submit to Durata its
non-binding information for long-term planning of its estimated requirements for the Product, split into resale and sampling quantities for the following [**] years or the remaining portion of this Agreement, whichever is shorter. This information
is for informational and planning purposes only and will not amend any Product Forecast or Purchase Order then in effect. 

3.3    Amending Forecasts. 

(a)    Non-binding Forecasts. Planned Orders are to be considered to be estimated forecasts for planning purposes
only and shall not be construed as a firm commitment by Durata to Angelini. Planned Orders may be reasonably increased or reduced by Angelini from time to time. 

(b)    Firm Orders. Once a Planned Order has become a Firm Order, it cannot be reduced, delayed, or increased by
Angelini without the written consent of Durata. 

 3.4    Purchase Orders. Angelini shall, together with its monthly
Product Forecast, deliver to Durata a written purchase order (“Purchase Order”) in respect of each Firm Order for which Angelini has not previously submitted a Purchase Order. Angelini will accompany its monthly update of the
Product Forecast with a new Purchase Order for each new Firm Order that was a Planned Order in the previous month’s Product Forecast. Each Purchase Order shall specify the Products ordered, the quantities of the Product ordered, and the
requested time, manner and address of delivery. 
 3.5    Order Size. Each Purchase Order shall specify a
quantity of Products that is consistent with a minimum batch size, on a country by country basis, of [**] vials of Product per country. Durata has the right not to fulfill any Purchase Order with respect to Products intended for a specific country
if such Purchase Order does not conform to the minimum batch size for such country. If Durata does not deliver the requested quantity ordered by Angelini within a deviation of ± [**]% Durata shall discuss in good faith with Angelini its
requirements for the requested quantity ordered and, unless Angelini determines that the requested quantity ordered (or any of it) is not required, Durata shall manufacture and deliver such remaining amounts (or such of them as may be required by
Angelini) to Angelini within [**] Business Days. 
 3.6    Durata’s Fulfillment of Purchase Orders. Durata
shall use Commercially Reasonable Efforts to satisfy Angelini’s Purchase Orders in accordance with their terms. 

3.7    Supply Failure. 

Durata shall be deemed to have failed to supply the Products (a “Supply Failure”), if: (i) Durata fails to deliver
Products (through its Authorized Manufacturers) as well as through its Back Up Manufacturer) in accordance with this Agreement (and ordered by Angelini in accordance with this Agreement) and, (ii) as a result, Angelini is unable to meet
customer orders for Products in a given country in the Territory after depleting all of the Safety Stock and all Back-up Stock (as defined below); 

For the avoidance of any doubt: 

1)    provided, that Angelini has, at all times, maintainedat least [**] months’ inventory (for each country in the
Territory) on hand as safety stock to protect based upon the average sales made by Angelini in such a period (such inventory, the “Back-up Stock”) and 

2)    the date on which a Supply Failure occurs is the date on which the circumstance described in the previous para
(ii) occurs (“Supply Failure Date”); 
 (a)    “). Further, any interruption of supply
experienced by Angelini when Angelini has less than [**] months’ of Back-up Stock on-hand of the applicable Product shall not be deemed a “Supply Failure”, unless Angelini’s failure to have [**] months’ Back-up Stock is due
to Durata’s failure to supply Product in accordance with this Agreement. In addition, for clarity, any shortage of Product due in whole or in part as a result of a Force Majeure event will not be considered a Supply Failure. 

 (b)    Quantity Limitation. In the event of a Supply Failure, Durata
shall be obliged to reallocate to Angelini, until such time as the Supply Failure has been cured, quantities of the Product that are within its inventory or reasonable control, on a pro rata basis, based on the prior year sales of the Product in the
Territory compared to the prior year total sales of the Product in all other territories (“Available Products”). In the event that the Supply Failure has not been cured by Durata within a period of [**] months from the Supply
Failure Date, this shall be considered a “Catastrophic Supply Failure”. 
 (c)    In the event of a
Catastrophic Supply Failure, in addition to the rights granted to Angelini under the Marketing License in the License Agreement Angelini shall, subject to Section 3.7 (d), have a non-exclusive license, effective as of the date of the
Catastrophic Supply Failure, under the Durata Patent Rights, the Durata Trademarks and the Durata Know How to the extent necessary to make, have made, and import the Product, including the right to manufacture and/or to have manufactured the Product
by a Permitted CMO (as defined in Section 3.7 (d) below). 
 (d)    In order to exercise its right to
manufacture the Product under Section 3.7 (c) and to receive any technology transfer under Section 3.7 (e) Angelini and any Permitted CMO shall enter into a confidentiality and non-use agreement with Durata protecting the Durata
Know-How relevant to the manufacture of the Product (the “Non-Use Agreement”). A “Permitted CMO” is a Third Party manufacturing organization selected by Angelini that is reasonably acceptable to Durata. Angelini
understands that in determining whether a Third Party manufacturing organization is acceptable, Durata may, acting reasonably, take into consideration, among other factors, Durata’s ability to enforce the Non-Use Agreement against such Third
Party. 
 (e)    Durata shall, within [**] days from the date of the Catastrophic Supply Failure, use Commercially
Reasonable Efforts to provide a technology transfer reasonably sufficient to permit Angelini (or its Permitted CMO) to manufacture or have manufactured the Product. 

(f)    Durata shall cooperate and reasonably support Angelini’s efforts to file the appropriate filings or otherwise
amend the applicable Regulatory Approvals in the Territory as well as the EMA Regulatory Approval for the Product to permit Angelini (or its Permitted CMO) to manufacture the Product pursuant to Section 3.7 (c) above. 

(g)    Notwithstanding Section 11.3, or any other provision, of the License Agreement, (i) Durata will have no
obligation to defend, indemnify or hold harmless Angelini (nor bear any other obligation or liability) with respect to Product Liability Claims arising from the manufacture of Products made by Angelini (or its Permitted CMO) following a Catastrophic
Supply Failure and (ii) Angelini will, pursuant to Section 11.3 of the License Agreement, indemnify Durata for any such Product Liability Claims arising from the manufacture of Products made by Angelini (or its Permitted CMO) following a
Catastrophic Supply Failure. 
 (h)    Except as stated above, all the other terms and conditions described in this
Agreement and the License Agreement shall remain fully valid and effective. 

 3.9    Safety Stock. For each of the Products, during the Term, Durata
undertakes to keep a rolling safety stock of Product exclusively dedicated to Angelini, in Bulk Form, equal or higher than the amount of Product ordered by Angelini in the previous [**] month period (the “Safety Stock”). 

ARTICLE IV 
 DELIVERY;
INVOICES 
 4.1    Delivery. 

(a)    All deliveries of the Product in Finished Goods Form shall be made by Durata ExWorks (INCOTERMS 2010) the
Facilities. Title and risk of loss will shift to Angelini upon delivery to the common carrier at the Facilities for shipment to Angelini’s warehouse located at Ancona, Italy, Europe, or such other locations in Europe as may be designated by
Angelini to Durata from time to time within [**] months from the date of receipt of the relevant order. Angelini will then be responsible for coordinating and executing all logistics and documentation required to move Product into those markets in
the Territory. 
 (b)    Notwithstanding the foregoing, Durata shall not be obligated to deliver the Products to more
than [**] locations requested by Angelini. 
 4.2    Certificates of Analysis. Durata shall provide to Angelini,
in preparation for each delivery of the Products, a Certificate of Analysis as specified in the Quality Agreement for each batch of Products delivered. 

4.3    Certificate of Origin. Durata shall, for customs purposes, upon delivery of the Products, provide Angelini
with a valid declaration of origin, in a form reasonably acceptable to Angelini, in respect of all Products supplied to Angelini under this Agreement, together with such other supporting documents relating to the origin of such Products as Angelini
may reasonably require. 
 4.4    Packaging. Durata shall package and label the Products appropriate for delivery
to end-users in accordance with the Specifications. 
 4.5    Method of Invoicing. All orders under this
Agreement shall be invoiced at the time of shipment. 
 ARTICLE V 

PRICE 

5.1    Product Price. Subject to Sections 5.2 and 5.3, the price for each vial of Product (the “Product
Price”) shall be [**] Euros (€[**]). 

 5.2    Price Changes. From the [**] anniversary of the Effective Date, Durata
shall have the right to increase the Product Price by [**] per year. In the event a generic product receives regulatory approval in the Territory, is commercialized, and affects Angelini’s revenues for the Product, the parties will discuss in
good faith the potential to reduce the Product Price. 
 5.3    Remittance of Payments. Payments due to Durata
under Section 5.1 shall be payable by Angelini no later than [**] days after the invoice date. Angelini shall make payment by wire transfer of Euros to a bank account designated by Durata or by such other payment method as the Parties may agree
upon from time to time. 
 5.4    Currency. All payments under this Agreement shall be made in Euro. 

5.5    Interest on Late Payments. Angelini shall be liable to pay interest to Durata at the average one-month
European Interbank Offered Rate (EURIBOR) for the Euro as reported from time to time in the Wall Street Journal plus [**] percent ([**]%), but in no event higher than the highest rate permissible under Law on all overdue amounts from the due date
until the date the amount is paid in full. 
 5.6    Deductions from Payments. 

(a)    Angelini will make all payments to Durata under this Agreement without deduction or withholding for taxes except to
the extent that any such deduction or withholding is required by applicable Law in effect at the time of payment. Any tax required to be withheld on amounts payable under this Agreement will promptly be paid by Angelini on behalf of Durata to the
appropriate governmental authority, and Angelini will furnish Durata with proof of payment of such tax. Any such tax required to be withheld will be an expense of and borne by Durata. 

(b)    Angelini and Durata will cooperate with respect to all documentation required by any taxing authority or reasonably
requested by Durata to secure a reduction in the rate of applicable withholding taxes. 
 5.7    Value Added Tax.
All payments under this ARTICLE V shall be exclusive of value added tax. Angelini shall pay for its own account all value added taxes as required by applicable Law. 

ARTICLE VI 
 TERM AND
TERMINATION 
 6.1    Term. This Agreement shall be in effect from the Effective Date and shall continue in
effect until the tenth (10th) anniversary of the launch of the first Product into the Territory, unless terminated pursuant to Section 6.2 (the “Initial Term”). 

6.2    Extended Term. Parties agree that at the expiry of the Initial Term above described, Angelini shall have the
right to extend the term of this Agreement up to ten (10) times, each for a period of one (1) year at the same terms and conditions described in this Agreement (each such one year period, an “Extended Term”), upon written
notice provided to Durata no later than ninety (90) days prior to the expiration of the Initial Term or each subsequent Extended Term. 

 6.3    Termination by Durata for breach. Durata shall be entitled to
terminate this Agreement in the event that Angelini commits a material breach of this Agreement and (i) the breach is incurable, or (ii) Angelini fails to cure such breach within [**] days of receiving a Notice of default from Durata (or
such longer period as Durata may reasonably agree if said breach is incapable of cure within such [**] days), by giving a Notice of termination to Angelini within [**] days of first becoming aware of such breach (if such breach is incurable) or
within [**] days of the end of such cure period. 
 6.4    Termination by Angelini for breach. Angelini shall be
entitled to terminate this Agreement in the event that Durata commits a material breach of this Agreement and (i) the breach is incurable, or (ii) Durata fails to cure such breach within [**] days of receiving a Notice of default from
Angelini (or such longer period as Angelini may reasonably agree if said breach is incapable of cure within such [**] days), by giving a Notice of termination to Durata within [**] days of first becoming aware of such breach (if such breach is
incurable) or within [**] days of the end of such cure period. Durata acknowledges that a Catastrophic Supply Failure would constitute a material breach of this Agreement for the purposes of this Section. The Parties acknowledge that if Angelini
terminates this Agreement as a result of a Catastrophic Supply Failure the License Agreement shall continue to the extent detailed in Section 14.4] of the License Agreement 

6.5    Cross Termination. If either Party terminates the License Agreement for material breach in accordance with
Section 14.2 of the License Agreement, such Party may by giving written notice to the other Party, terminate this Agreement,, immediately as of the date specified in the notice of termination. 

6.6    Effect of Termination. Termination of this Agreement for any reason is without prejudice to the
Parties’ accrued rights and shall not be construed to release either Party of any obligation matured prior to the effective date of such termination. Except where this Agreement is terminated by Angelini as a result of a Catastrophic Supply
Failure (in which case Angelini shall have the rights of manufacture detailed in Section 3.7), Angelini shall have no right or license to manufacture Products upon or after expiration or termination of this Agreement. 

6.7    Survival. Sections 5.3, 6.6, 6.7, ARTICLE VIII, and ARTICLE X shall survive the expiration or termination of
this Agreement. 
 ARTICLE VII 

REPRESENTATIONS AND WARRANTIES 

7.1    Representations and Warranties. Durata and Angelini each represents and warrants to the other that: 

 (a)    Duly Executed. This Agreement has been duly executed and
delivered by such Party and constitutes a legal, valid and binding obligation of such Party, enforceable against such Party in accordance with its terms, except as such enforceability may be limited by applicable insolvency and other laws affecting
creditors’ rights generally or by the availability of equitable remedies. 
 (b)    Duly Authorized; No
Conflicts. The execution, delivery and performance of this Agreement by such Party and all instruments and documents to be delivered by such Party hereunder and the performance of such Party’s obligations hereunder 

 

	 	(i)	are within the corporate power of such Party; 

  

	 	(ii)	have been duly authorized by all necessary or proper corporate action; 

  

	 	(iii)	do not conflict with any provision of the charter documents of such Party; 

  

	 	(iv)	do not conflict with or violate any requirement of applicable Laws; 

  

	 	(v)	do not and will not conflict with, violate or breach or constitute a default or require any consent under, any contractual obligations of such Party, except such consent as shall have been obtained prior to the
Effective Date; and 

  

	 	(vi)	do not and will not require any filing or registration with or the license, permit, consent, approval or authorization of or any notice to any Governmental Authority, except such as shall have been obtained prior to the
Effective Date. 

 (c)    Duly Organized. It: 

 

	 	(i)	is a company duly organized, validly existing and in good standing under the Laws of its jurisdiction of incorporation; 

  

	 	(ii)	is duly qualified as a corporation and in good standing under the Laws of each jurisdiction where its ownership or lease of property or the conduct of its business requires such qualification, where the failure to be so
qualified would have a material adverse effect on its financial condition or its ability to perform its obligations hereunder; 

  

	 	(iii)	has the requisite corporate power and authority and the legal right to conduct its business as now conducted and hereafter contemplated to be conducted; 

	 	(iv)	has all necessary licenses, permits, consents, authorizations or approvals from or by, and has made all necessary notices to, all Governmental Authorities having jurisdiction, to the extent required for such ownership
and operation; and 

  

	 	(v)	is in compliance with its organizational documents. 

 (d)    Warranty by
Durata. Durata hereby represents and warrants to Angelini that the quality (purity, physical and chemical properties) of the Products supplied by it to Angelini shall be in accordance with their respective Specifications and the Quality
Agreement. This warranty is exclusive and is in lieu of all other warranties, whether written or oral express, implied or statutory including any such warranties of merchantability, satisfactory quality or fitness for any purpose and, also in view
of article 7:17 of the Dutch Civil Code, exhaustively reflects all of the characteristics Angelini may reasonably expect the Products to have. Further, the parties agree that this Agreement is not governed by the United Nations Convention on the
International Sale of Goods, the application of which is hereby expressly excluded. 
 ARTICLE VIII 

REMEDIES FOR NON-CONFORMING PRODUCT 

8.1    Non-Conforming Product. 

(a)    Durata shall promptly notify Angelini of any Non-Conforming Product of which it becomes aware, which have been
delivered to Angelini, specifying the release testing of the Product and the relevant Master Batch Record. 

(b)    Angelini shall notify Durata of any Non-Conforming Product within (i) [**] business days of Angelini’s
receipt of such Non-Conforming Product in the event of a defect discovered by Angelini through the use of reasonable testing methods and procedures mutually agreed to by the Parties or (ii) during the full shelf life of the product within [**]
Business Days of Angelini’s confirmation of the Non-Conforming status of the Product in the event of a defect (latent or otherwise) which was not discovered through the use of such testing methods and procedures. Durata shall have the right to
examine and test any Product in Angelini’s possession that Angelini claims is Non-Conforming. The Parties shall cooperate to determine the point at which the Product became Non-Conforming. 

8.2    Disagreement. In case Durata and Angelini cannot agree as to whether a certain quantity of the Product
delivered complies with the Specifications, then the situation shall be referred to an independent analytical laboratory mutually acceptable to both Parties for resolution. The resolution shall be final and binding on the Parties. The costs
associated with the resolution proceedings shall be borne by the losing Party. 
 8.3     Remedies for
Non-Conformance. Angelini shall be entitled to the replacement of any Non-Conforming Products delivered to Angelini by Durata with corresponding Product meeting their respective Specifications to be delivered within the

 
lead time described in Section 4.1. Durata shall not be responsible for Non-Conforming Products if the Non-Conformance arose (i) after receipt of the Product by Angelini (including,
without limitation, as a result of improper storage by Angelini of the Product) or (ii) as a result of any change in artwork, labelling, product inserts and other packaging designs for the Product requested by Angelini and/or required a
Governmental Authority in the Territory. Durata shall bear the costs of freight and insurance for return of the Non-Conforming Products which must be replaced by Durata pursuant to this Section 8.3. Angelini shall, at Durata’s option and
cost, either return to Durata at the Facility or destroy the Non-Conforming Products. Except as set forth in this Section 8.3 and Section 11.3 of the License Agreement, Durata shall have no liability for Non-Conforming Product, and
Angelini’s sole remedy shall be as set forth in this Section 8.3 and Section 11.3 of the License Agreement. 
 ARTICLE IX

 REGULATORY MATTERS 

9.1    Government Inspections. In the event that Durata or any Affiliate or Third Party contractor of Durata is
audited or inspected by the EMA (or any other Governmental Authority whose inspection might reasonably be expected to impact the EMA certification of the relevant facility) with respect to a facility used for Processing the Products pursuant to this
Agreement, Durata shall promptly (but in any event, within [**]) notify Angelini of such audit or inspection as well as of any alleged violations or deficiencies. Durata shall use Commercially Reasonable Efforts to correct all such deficiencies in a
timely manner and advise Angelini periodically of progress being made, as well as when all such deficiencies have been corrected. 

ARTICLE X 
 GENERAL
PROVISIONS 
 10.1    Confidentiality. From the Effective Date, all information proprietary or confidential
to a Party that the other Party acquires through its participation in the negotiation and performance of this Agreement shall be considered Confidential Information subject to Article VIII of the License Agreement. 

10.2    Relationship of the Parties. Each Party shall bear its own costs incurred in the performance of its
obligations hereunder without charge or expense to the other except as expressly provided in this Agreement. For all purposes, and notwithstanding any other provision of this Agreement to the contrary, Angelini’s legal relationship under this
Agreement to Durata shall be that of independent contractor. Nothing in this Agreement shall be construed to establish a partnership or joint venture, or a relationship of co-partners or joint venturers between the Parties. 

10.3    Limitation of Liability. TO THE EXTENT PERMITTED BY LAW, NOTWITHSTANDING ANY OTHER PROVISION CONTAINED
HEREIN, UNLESS RESULTING FROM A PARTY’S FRAUDULENT BEHAVIOR, IN NO EVENT SHALL DURATA, ON THE ONE HAND, OR ANGELINI, ON THE OTHER HAND, BE LIABLE TO THE OTHER OR ANY OF THE OTHER’S AFFILIATES FOR ANY

 
CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING, WITHOUT LIMITATION, LOST PROFITS, BUSINESS OR GOODWILL) SUFFERED OR INCURRED BY SUCH OTHER PARTY OR ITS
AFFILIATES IN CONNECTION WITH A BREACH OR ALLEGED BREACH OF THIS AGREEMENT. 
 10.4    Force Majeure. The
occurrence of an event that materially interferes with the ability of a Party to perform its obligations or duties hereunder which is not within the reasonable control of the Party affected, not due to such Party’s malfeasance, and which could
not with the exercise of due diligence have been avoided (“Force Majeure”), including, but not limited to, an injunction, order or action by a Governmental Authority, fire, accident, labor difficulty, strike, riot, civil commotion,
act of God, delay or errors by shipping companies or change in Law, shall not excuse such Party from the performance of its obligations or duties under this Agreement, but shall merely suspend such performance during the continuation of Force
Majeure. The Party prevented from performing its obligations or duties because of Force Majeure shall promptly notify the other Party hereto (the “Other Party”) of the occurrence and particulars of such Force Majeure and shall provide the
Other Party, from time to time, with its best estimate of the duration of such Force Majeure and with notice of the termination thereof. The Party so affected shall use reasonable efforts to avoid or remove such causes of nonperformance. Upon
termination of Force Majeure, the performance of any suspended obligation or duty shall promptly recommence. 

10.5    Choice of Law. All disputes, claims or controversies arising out of, relating to or in connection with this
Agreement (“Disputes”), including any question regarding its formation, existence, validity, enforceability, performance, interpretation or termination, shall be governed by the laws of the Netherlands (without reference to its
choice of law or conflicts of law rules).  
 10.6    Dispute Resolution. The Parties irrevocably agree
that any dispute, controversy or claim arising out, of or in relation to this Agreement, including the validity, invalidity, breach or termination thereof, will be settled by arbitration in accordance with the Rules of the International Chamber of
Commerce in force on the date when the notice of arbitration is submitted. The number of arbitrators will be three (3). The seat of arbitration will be London, England. The arbitral proceedings will be conducted in English. 

10.7    Remedies Cumulative. The remedies set forth in this Agreement (including without limitation termination
rights) are cumulative and shall not be construed to restrict or otherwise affect any other remedies that may be available under any other agreement or under Law. 

10.8    Assignment. This Agreement may not be assigned by either Party without the prior consent of the other
Party; provided, however, that each Party shall have the right to assign its rights and obligations under this Agreement to any Third Party successor to all or substantially all of (i) its entire business or (ii) its pharmaceutical
business. It is further understood and agreed that each Party shall assign, or otherwise 

 
cause to be performed, its obligations under this Agreement (including, without limitation, obligations of confidentiality, processing and payment) to or by, as the case may be, one or more of
its Affiliates to the extent necessary or appropriate in order to ensure that such obligations are fulfilled in accordance with the terms and intent of this Agreement, provided, however, that in the event a Party causes any of its obligations to be
performed by an Affiliate, such Party shall guarantee such performance. This Agreement shall be binding upon, and subject to the terms of the foregoing sentence, inure to the benefit of the Parties hereto, their successors, legal representatives and
assigns. 
 10.9    Notices. All demands, notices, consents, approvals, reports, requests and other
communications hereunder (“Notices”) must be in writing and will be deemed to have been duly given only if delivered personally, by facsimile transmission (against confirmed receipt), by certified or registered mail, return receipt
requested, or by overnight delivery using a globally-recognized carrier, to the Parties at the following addresses or facsimile numbers: 
  

			
	 Durata:
	  	Spaces Zuidas II,
		  	Kantoor 4.03
		  	1083 HN Amsterdam,
		  	The Netherlands
		  	Attn: General Manager
		  	
	 With copy to:
	  	Durata Therapeutics, Inc.
		  	200 S. Wacker, Suite 2550
		  	Chicago, IL 60606
		  	Attn: General Counsel
		  	Phone: 312-219-7000
		  	Email: bhecht@duratatx.com

 And, a copy which shall not constitute notice to: 

 

			
		  	Morrison & Foerster LLP
		  	2000 Pennsylvania Avenue, N.W.
		  	Washington, D.C. 20006
		  	Attention: Van Ellis
		  	Phone: 202-887-8776
		  	Email: vellis@mofo.com
		  	
	 Angelini:        
	  	Viale Amelia 70
		  	00181 – Rome
		  	Italy
		  	Attn: CEO Ing.Gianluigi Maria Frozzi
		  	Phone: +39 06 70853283
		  	Email: legale@angelini.it
		  	

			
	 With copy to:
	  	Finaf S.p.a.
		  	Viale Amelia 70
		  	00181 – Rome
		  	Italy
		  	Attn: Adelmo Di Michele
		  	Phone: +39 06 70853269
		  	Email: a.dimichele@angelini.it

 or to such other address as the addressee shall have last furnished in writing in accord with this provision to the addressor.
All Notices shall be deemed effective upon receipt by the addressee. 
 10.10    Invalid Provisions. If any
provision of this Agreement is held to be illegal, invalid or unenforceable under any applicable present or future Law (the “Unenforceable Provision”), then such Unenforceable Provision will be fully severable, and the remaining
provisions of this Agreement will remain in full force and effect and will not be affected by the Unenforceable Provision or by its severance herefrom. 

10.11    Headings. The headings used in this Agreement have been inserted for convenience of reference only and do
not define or limit the provisions hereof. 
 10.12    Waiver. Any term or condition of this Agreement may be
waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. No waiver by any Party
of any term or condition of this Agreement, in any one or more instances, shall be deemed to be or construed as a waiver of the same or any other term or condition of this Agreement on any future occasion. The failure of either Party at any time or
times to require performance of any provision hereof shall in no manner affect its rights at a later time to enforce the same. 

10.13    Entire Agreement. This Agreement (including the exhibits and schedules hereto), the License Agreement and
the Quality Agreement constitute the entire agreement between the Parties hereto with respect to the within subject matter and supersedes all previous agreements and understandings between the Parties, whether written or oral. In the event of any
inconsistency between the terms of this Agreement and the License Agreement, the License Agreement terms, including its dispute resolution terms, shall prevail. This Agreement may be altered, amended or changed only by a writing making specific
reference to this Agreement and signed by duly authorized representatives of Durata and Angelini. 
 10.14    No
License. Nothing in this Agreement shall be deemed to constitute the grant of any license or other right in either Party to or in respect of any product, patent, trademark, Confidential Information, trade secret or other data or any other
intellectual property of the other Party except as expressly set forth herein. 
 10.15    Third Party
Beneficiaries. None of the provisions of this Agreement shall be for the benefit of or enforceable by any Third Party, including, without limitation, any creditor of either Party hereto. No such Third Party shall obtain any right under any
provision of this Agreement or shall by reasons of any such provision make any Claim in respect of any debt, liability or obligation (or otherwise) against either Party hereto. 

 10.16    Counterparts. This Agreement may be executed in any two or
more counterparts, each of which, when executed, shall be deemed to be an original and all of which together shall constitute one and the same document. 

10.17    Compliance with Law. Notwithstanding any other provision of this Agreement, neither Party shall be
required to undertake any activity or obligation under this Agreement which it has reason to believe may violate any Laws; provided, however, a Party which so believes shall promptly inform the other Party of such belief. Furthermore, Durata shall
ensure that all Product supplied to Angelini hereunder shall be manufactured in compliance with the relevant requirements of Governmental Authorities, and applicable Laws, including, without limitation, all Laws applicable to the transportation,
storage, use, handling and disposal of hazardous materials used to manufacture Product. Durata shall obtain and maintain, at its expense, for so long as Durata is supplying Product to Angelini hereunder, all facility licenses and government permits,
including, without limitation, health, safety, and environmental permits, necessary for the conduct of the actions and procedures undertaken to manufacture and supply the Product for importation and sale to Angelini. 

10.18    List of Exhibits 

A          Compound 

B          Facilities 

C          Authorized Manufacturers 

D          Products 

E          Specifications 

F          Quality Agreement (minimum clauses) 

THE BALANCE OF THIS PAGE IS LEFT BLANK INTENTIONALLY 

 IN WITNESS WHEREOF, the Parties hereto have caused this Supply Agreement to be executed by their respective
officers hereunto duly authorized as of the Effective Date. 
  

					
	DURATA TH. INT. B.V.(NL)
		
	By:	 	/s/ Corey Fishman
		 	Name:	 	Corey Fishman
		 	Title:	 	Director

  

					
		
	By:	 	/s/ Alexander Van Oyen
		 	Name:	 	Alexander Van Oyen
		 	Title:	 	Managing Director

  

					
	ACRAF S.P.A.
		
	By:	 	/s/ Gianluigi Maria Frozzi
		 	Name:	 	Gianluigi Maria Frozzi
		 	Title:	 	Managing Director

 EXHIBIT A 

Compound 
 Dalbavancin drug substance is a
semi-synthetic antibiotic manufactured by chemical modification of homologues of the lipoglycopeptide antibiotic A-40,926 which is produced through a fermentation process. 

Dalbavancin drug substance is a mixture of five closely related homologues that can be grouped into two structural families, designated dalbavancin A
(subtypes A0 and A1) and dalbavancin B (subtypes B0, B1, and B2). The components that comprise dalbavancin drug substance all share the same core structure (Table A-1). These homologues differ
from one another primarily in the length and/or branching of their respective fatty acid side chains on the N-acylaminoglucuronic acid moiety (designated as R1) and/or the presence of an
additional methyl group (designated as R2) on the terminal amino group. Dalbavancin drug substance is a hydrochloride salt. 

Dalbavancin drug substance is isolated as a hydrochloric acid salt. However, the active moiety is the free base form. The dalbavancin drug product strength
(i.e. 500 mg per vial) is reported as the free base form. The free base structure is provided below. 
 Figure A-1 General Structure of Dalbavancin Drug
Substance 
  
 

 

 Table A-1 Substitution Patterns for Dalbavancin Homologues 

 

							
	Homologue	 	R1	 	Number of Carbons R1	 	R2
	 A0
	 	CH(CH3)2	 	3	 	H
	 A1
	 	CH2CH2CH3	 	3	 	H
	 B0
	 	CH2CH(CH3)2	 	4	 	H
	 B1
	 	CH2CH2CH2CH3	 	4	 	H
	
B2
	 	CH2CH(CH3)2
	 	4	 	CH3

 The major dalbavancin homolog is dalbavancin B0. 

Figure A-2 Structure of Dalbavancin B0 

 
 

 
 The B0 INN chemical name is:
5,31-dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56-O-[2-deoxy-2-[(10-methylundecanoyl)amino]-ß-D-glucopyranuronosyl]-38-[[3-(dimethylamino)propyl]
carbamoyl]-42-O-a-D-mannopyranosyl-15-N-methyl(ristomycin A aglycone) hydrochloride. 

 EXHIBIT B 

Facilities 
 Gnosis Bioresearch S.r.l –
75010 Pisticci Sala, Pisticci, Italy 
 Hospira Inc., 1776 Centennial Drive, McPherson, KS 67460, USA 

 EXHIBIT C 

Authorized Manufacturers 
 Gnosis Bioresearch
S.r.l – 75010 Pisticci Sala, Pisticci, Italy 
 Hospira Inc., 1776 Centennial Drive, McPherson, KS 67460, USA 

 EXHIBIT D 

Products 
 The “Product” Dalbavancin
for Injection, 500 mg, also known as << XYDALBATM>> , is supplied in single-use, clear glass vials as a sterile, lyophilized, preservative-free, white to off-white to pale yellow solid. Each vial contains dalbavancin HCl equivalent
to 500 mg of anhydrous dalbavancin as the free base, plus lactose monohydrate and mannitol as excipients. Sodium hydroxide or hydrochloric acid may be added to adjust the pH at the time of manufacture. The powder is to be reconstituted and further
diluted for IV infusion 
 The container closure system consists of a 48 mL glass vial with a rubber stopper and flip-off seal. 

Table B-1 Quantitative Composition of Dalbavancin for Injection, 500 mg Vials 

 

					
	Ingredient	 	Quantity per Viala	 	Function
			
	             Dalbavancin
	 	[**] mgb	 	Active Ingredient
			
	             Mannitol
	 	128.8 mg	 	Bulking Agent
			
	             Lactose Monohydrate
	 	128.8 mg	 	Bulking Agent
			
	             Water for
Injectionc
	 	–	 	Solvent
			
	             Sodium
hydroxided
	 	–	 	pH adjustment
			
	             Hydrochloric
acidd
	 	–	 	pH adjustment
			
	             Total
Weight
	 	[**] mg	 	 

  

	a 	Vials contain a [**]% overfill to ensure withdrawal of the label claim from each reconstituted vial. 

	b 	Anhydrous dalbavancin free base. 

	c 	Removed by lyophilization. 

	d 	Added as a solution in water for pH adjustment 

 A pack of Product is of one vial 

 EXHIBIT E 

Specifications 
 Minimum batch size per country
in the Territory is [**] vials of Product in Finished Goods Form. 

 EXHIBIT F 

Quality Agreement (minimum clauses) 
 The
Authorized Manufacturers of the pharmaceutical product are responsible for certifying that the API is manufactured under GMP (EUGMP Part II, ICH Q7 Guide and any other applicable territory GMP guidelines/requirements) including re-packaging,
re-labeling or dividing-up of API. 
 All of the activities such as procuring, holding, supplying or exporting the API have to be performed in compliance
with the European Commission Guidelines on the Principles of Good Distribution Practices for API for Medicinal Products for Human Use and any other applicable territory GDP guideline/requirements. 

The Authorized Manufacturers of the pharmaceutical product shall verify compliance with applicable territory GMP and GDP by conducting audits at the
manufacturing and distribution sites of the API manufacturer. 
 The Authorized Manufacturers of the pharmaceutical product shall verify such compliance
themselves or, without prejudice to Directive 2011/62/EU, through an entity acting on their behalf under a contract. 
 A written confirmation that the
Authorized Manufacturers of the pharmaceutical product have verified the compliance of the API manufacturer with applicable territory principles and guidelines of good manufacturing practice by conducting audits is mandatory. 

The written confirmation shall contain a reference to the date of the audit and a declaration that the outcome of the audit confirms that the API
manufacturing complies with the principles and guidelines of good manufacturing practice in the US and EU. 
 The Authorized Manufacturers of the
pharmaceutical product shall have a written contract in place with manufacturers of API and shall audit such manufacturers, in the absence of critical quality incidence, at least [**], providing Angelini at least an abstract of the audit report.

 The Authorized Manufacturers of the pharmaceutical product shall inform within [**] business days Angelini of any major GMP deviation relevant to these
API. 
 The Authorized Manufacturers of the pharmaceutical product are responsible to certify that the API manufacturer has the supply chain traceability of
starting materials, intermediates, reagents used for the manufacture of the API that should be established and documented. 
 This documentation should be
made available for inspection at the request of the Angelini and competent authorities. 

 The holders of the manufacturing authorization of the pharmaceutical product shall inform within [**] business
days Angelini of any major GMP deviation relevant to these GMP- starting materials. 
 The Authorized Manufacturers 

The holders of the manufacturing authorization of the pharmaceutical product shall ensure that the excipients are suitable for use in medicinal products by
ascertaining what the appropriate good manufacturing practice is. 
 This shall be ascertained on the basis of a formalised risk assessment in accordance
with the applicable US/EU guidelines. 
 Such risk assessment shall take into account requirements under other appropriate quality systems as well as the
source and intended use of the excipients and previous instances of quality defects. 
 The Authorized Manufacturers of the pharmaceutical product shall
ensure that the appropriate good manufacturing practice so ascertained, is applied. 
 The Authorized Manufacturers of the pharmaceutical product shall
verify the presence of metals listed in ICHQ3D, in EMEA/CHMP/SWP/4446/2000 and in USP <232> and <233> in the finished product supplied to Angelini. 

This shall be ascertained on the basis of a formalised risk assessment in accordance with the ICHQ3D requirements. 

Based on the risk assessment outcome the Authorized Manufacturers of the pharmaceutical product shall develop selective and quantitative analytical methods to
verify that the content of each potential elemental impurity is within the limit calculated from the PDE defined by the ICH Q3D. 
 The need to add a
specification for the elemental impurity control ([routine o by skip] has to be also evaluated and shared with Angelini. 
 The Authorized Manufacturers of
the pharmaceutical product shall: 
  

	 	•	 	inform the competent authority and the marketing authorisation holder immediately if Durata obtains information that medicinal products products which come under the scope of their manufacturing authorizations are, or
are suspected of being, falsified irrespective of whether those medicinal products were distributed within the legal supply chain or by illegal means, including illegal sale by means of information society services; 

 

	 	•	 	verify that the manufacturers, importers or distributors from whom Durata obtains active substances are registered with the competent authority of the US or applicable EU Member State in which they are established, if
applicable; and 

  

	 	•	 	verify the authenticity and quality of the active substances and the excipients.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}]]